Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mip pharma croatia d.o.o., mihanovićeva 14, zagreb, hrvatska - laktuloza, tekuća - sirup - 65 g/100 ml - urbroj: 100 ml sirupa sadrži 65 g laktuloze u obliku laktuloze, tekuće

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mark medical d.o.o. budmanijeva 5 10000 zagreb -

Europska Unija - hrvatski - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - chlormethine - mycosis fungoides - antineoplastična sredstva - ledaga je indicirana za topičko liječenje limfoma t-stanica (tipa mf-tipa ctcl) tipa mikoza fungoida u bolesnika odraslih.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastična sredstva - panretin gel namijenjen je za lokalno liječenje kožnih lezija kod bolesnika s kupljenom-imunodeficijencije sindrom (aids-a)-recenzije kaposijev sarkom (sk) kada:poraz ne изъязвленной ili lymphoedematous, i;liječenje висцеральные policajac nije potrebna, i osip ne reagira na sistem антиретровирусной terapije, i radioterapije ili kemoterapije se ne uklapaju.

Europska Unija - hrvatski - EMA (European Medicines Agency)

galderma international - brimonidin tartrat - bolesti kože - ostali dermatološki pripravci - mirvaso je indiciran za simptomatsko liječenje eritema grudi rosacea kod odraslih pacijenata.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

galenika d.o.o. - heparin - gel - 300 i.j./1 g - 1 g gela sadrži: 300 i.j. heparinnatrijuma

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

adriatic bst d.o.o., verovškova ulica 55, ljubljana, slovenija - paracetamol gvaifenezin fenilefrinklorid - prašak za oralnu otopinu - 500 mg + 200 mg + 10 mg - urbroj: svaka vrećica sadrži 500 mg paracetamola, 200 mg gvaifenezina i 10 mg fenilefrinklorida

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

galenika d.o.o. - heparin - krem - 300 i.j./1 g - 1 g krema sadrži: 300 i.j. heparinnatrijuma

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.